Journal of neurology · 2025
Tenecteplase compared to alteplase before mechanical thrombectomy enhances 1-h recanalization and reduces disability in large-vessel occlusion.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Lu, Li Jialu, Wu Xiao, Li Lulan, Jiao Xueqiao, Che Fengyuan, Han Hongxing, Zhang Liyong, Liu Weidong, Wang Peifu, Yang Fuxia, Zhang Fangfang, Ji Xunming, Guo Xiuhai
Аннотация
BACKGROUND: The comparative efficacy of tenecteplase versus alteplase in achieving early recanalization (ER) before mechanical thrombectomy (MT) for large-vessel occlusion (LVO) remains uncertain.
METHODS: This study was a retrospective analysis of prospectively collected data of consecutive patients with LVO underwent intravenous thrombolysis (IVT) and brain angiography between January 2022 and December 2023. ER was defined as ≥ 50% reperfusion or absence of retrievable thrombus on initial angiography.
RESULTS: 146 patients received tenecteplase and 307 received alteplase. Tenecteplase shortened door-to-IVT time (33 vs. 39 min, P < 0.001) and door-to-puncture time (97 vs. 109 min, P = 0.039) compared to alteplase. Overall ER rates did not differ significantly (17.1% vs. 12.1%, P = 0.223). However, a significant interaction was observed between thrombolytic agent and IVT-to-puncture time (Pinteraction = 0.034): tenecteplase achieved higher ER rates when IVT-to-puncture time was < 60 min (17.2% vs. 5.0%, aOR, 4.13 [95% CI 1.24-13.74]). With IVT-to-puncture time ≥ 60 min, ER rates were similar (17.2% vs. 16.8%, aOR 0.91 [95% CI 0.43-1.91]). No ER differences were noted across occlusion sites, clot burden, NIHSS, sex, and age. At 3 months, tenecteplase reduced disability rates (mRS 0-3: 73.5% vs. 65.7%, P = 0.041). Functional independence (mRS 0-2) was 57.4% with tenecteplase and 53.1% with alteplase (P = 0.301).
CONCLUSIONS: Real-world observations reveal tenecteplase has increased ER rates compared to alteplase within 1 h of IVT and reduced disability in LVO patients. Further randomized trials are warranted to evaluate the effect of tenecteplase rapid bridging mechanical thrombectomy.
METHODS: This study was a retrospective analysis of prospectively collected data of consecutive patients with LVO underwent intravenous thrombolysis (IVT) and brain angiography between January 2022 and December 2023. ER was defined as ≥ 50% reperfusion or absence of retrievable thrombus on initial angiography.
RESULTS: 146 patients received tenecteplase and 307 received alteplase. Tenecteplase shortened door-to-IVT time (33 vs. 39 min, P < 0.001) and door-to-puncture time (97 vs. 109 min, P = 0.039) compared to alteplase. Overall ER rates did not differ significantly (17.1% vs. 12.1%, P = 0.223). However, a significant interaction was observed between thrombolytic agent and IVT-to-puncture time (Pinteraction = 0.034): tenecteplase achieved higher ER rates when IVT-to-puncture time was < 60 min (17.2% vs. 5.0%, aOR, 4.13 [95% CI 1.24-13.74]). With IVT-to-puncture time ≥ 60 min, ER rates were similar (17.2% vs. 16.8%, aOR 0.91 [95% CI 0.43-1.91]). No ER differences were noted across occlusion sites, clot burden, NIHSS, sex, and age. At 3 months, tenecteplase reduced disability rates (mRS 0-3: 73.5% vs. 65.7%, P = 0.041). Functional independence (mRS 0-2) was 57.4% with tenecteplase and 53.1% with alteplase (P = 0.301).
CONCLUSIONS: Real-world observations reveal tenecteplase has increased ER rates compared to alteplase within 1 h of IVT and reduced disability in LVO patients. Further randomized trials are warranted to evaluate the effect of tenecteplase rapid bridging mechanical thrombectomy.